“TrialConnect™ reflects the American Brain Tumor Association’s commitment to providing patients and their families with the most current information on new and alternative treatments," said Executive Director Elizabeth Wilson.
Des Plaines, IL (Vocus/PRWEB) February 24, 2011
The American Brain Tumor Association today launched TrialConnect™, a service that links brain tumor patients with appropriate clinical trials based on the patient’s tumor type and treatment history. The free and confidential service, administered by EmergingMed, is offered in English and Spanish.
“TrialConnect™ reflects the American Brain Tumor Association’s commitment to providing patients and their families with the most current information on new and alternative treatments as well as assistance in understanding and accessing them,” said Executive Director Elizabeth Wilson.
Clinical trials test the safety and effectiveness of treatments that have already shown significant promise in laboratory studies. For patients, clinical trials provide access to therapies that would otherwise be unavailable. Clinical trials are overseen by government and local hospital boards, and subject to rigorous regulation and oversight.
A TrialConnect™ specialist can be accessed via telephone at 877-769-4833, Monday-Friday, from 8:30 a.m. to 6:30 p.m. EST. Interested individuals can also access TrialConnect™ online at http://www.abtatrialconnect.org. After completing a confidential patient profile, the TrialConnect™ specialist will search open clinical trials, and reach out to prospective study sites for more information. Specialists remain in contact with patients throughout the process to answer questions and provide support.
For more information on this and other brain tumor patient and family services, visit the ABTA website at http://www.abta.org or call 1.800.886.ABTA(2282).
Founded in 1973, the American Brain Tumor Association was the first non-profit organization dedicated to funding brain tumor research. Today, the ABTA is a catalyst for research-based breakthroughs in brain tumor prevention, diagnosis and treatment and recognized as the leading resource in patient-centered brain tumor information, education and support.
# # #